Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
NGNE compared with STOK: revenue, margins and what each company keeps, and the suppliers and customers both name
NGNE
Neurogene Inc.
Change
Mkt cap
Revenue
Revenue
STOK
Stoke Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
NGNE
Neurogene Inc.
vs
STOK
Stoke Therapeutics, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Supply-chain overlap
Desk
News
Calendar
Saved
Search
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only NGNE
0
None
Shared
0
No disclosed counterparties: NGNE.
Only STOK
3
BIIB
Biogen International GmbH
customer
ACAD
Acadia Pharmaceuticals
customer
—
NWALP PHOP Property Owner
unlisted
supplier
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
NGNE
Neurogene Inc.
Change
27.60
▲
+3.73%
Mkt cap
$600.1M
Revenue
$925,000
Q2 FY24
Revenue
—
STOK
Stoke Therapeutics, Inc.
Change
27.32
▲
+3.17%
Regular session
Nov 3 '26
Mkt cap
$1.7B
Revenue
$9M
Q2 FY26
Revenue
$184M
FY25
vs
Compare
Regular session
Nov 3 '26
NGNE
Neurogene Inc.
vs
STOK
Stoke Therapeutics, Inc.
27.60
▲
+3.73%
Price
27.32
▲
+3.17%
$600.1M
Mkt cap
$1.7B
Q2 FY24
$925,000
Revenue
$9M
Q2 FY26
—
Revenue
$184M
FY25
Change
Change
NGNE
27.60
▲
+3.73%
vs
STOK
27.32
▲
+3.17%
Regular session
Nov 3 '26